

DAFTAR PUSTAKA

- Adi, S, S., Novida, H., Rudijanto, A., Soewondo, P., Suastika, K., Manaf, A., Sanusi, H., Lindarto, D., Shahab, A., Pramono, B., Asri, L, Y., Purnamasari, D., Nathalia, S, N., Ratna, S, M., Pande, D, M., Yuwono, A., Sasiarini, L., Sugiarto, W, S, K., Zufry, H. (2015). Konsensus Pengelolaan Dan Pencegahan Diabetes melitus tipe 2 Di Indonesia. PB. PERKENI
- Aerts, L., & Van Assche, F. A. (2003). Intra-uterine transmission of disease. *Placenta*, 24(10), 905-911.
- Aguiree, F., Brown, A., Cho, N.H., Dahlquist, G., Dodd, S., Dunning, T., Hirst, M., Hwang, C., Magliano, D., Patterson, C. and Scott, C., (2013). IDF diabetes atlas.
- Arimany-Nardi, C., Koepsell, H., & Pastor-Anglada, M. (2015). Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions. *The Pharmacogenomics Journal*, 15(6), 473-487.
- Bachmakov, I., Glaeser, H., Fromm, M. F., & König, J. (2008). Interaction of Oral Antidiabetic Drugs With Hepatic Uptake Transporters Focus on Organic Anion Transporting Polypeptides and Organic Cation Transporter 1. *Diabetes*, 57(6), 1463-1469.
- Becker, M., Visser, L., van Schaik, R., Hofman, A., Uitterlinden, A., & Stricker, B. (2009). Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. *The pharmacogenomics journal*, 9(4), 242-247.
- Boney, C. M., Verma, A., Tucker, R., & Vohr, B. R. (2005). Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. *Pediatrics*, 115(3), e290-e296.
- Brüning, J. C., Winnay, J., Bonner-Weir, S., Taylor, S. I., Accili, D., & Kahn, C. R. (1997). Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. *Cell*, 88(4), 561-572.
- Bugianesi, E., McCullough, A. J., & Marchesini, G. (2005). Insulin resistance: a metabolic pathway to chronic liver disease. *Hepatology*, 42(5), 987-1000.
- Chen, Ligong, Bradley Pawlikowski, Avner Schlessinger, Swati S. More, Doug Stryke, Susan J. Johns, Michael A. Portman et al., (2010), Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. *Pharmacogenetics and genomics* 20, no. 11: 687.
- Christensen, M. M., Brasch-Andersen, C., Green, H., Nielsen, F., Damkier, P., Beck-Nielsen, H., & Brosen, K. (2011). The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. *Pharmacogenetics and genomics*, 21(12), 837-850.

- Cline, Gary W., Kitt Falk Petersen, Martin Krssak, Jun Shen, Ripudaman S. Hundal, Zlatko Trajanoski, Silvio Inzucchi, Alan Dresner, Douglas L. Rothman, and Gerald I. Shulman., (1999), Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. *New England Journal of Medicine* 341, no. 4: 240-246.
- Cnop, Miriam, P. J. Havel, K. M. Utzschneider, D. B. Carr, M. K. Sinha, E. J. Boyko, B. M. Retzlaff, R. H. Knopp, J. D. Brunzell, and Steven E. Kahn., (2003), Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. *Diabetologia* 46, no. 4: 459-469.
- DeFronzo, R. A., & Ferrannini, E. (1991). Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. *Diabetes care*, 14(3), 173-194.
- DeFronzo, R. A., & Goodman, A. M. (1995). Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. *New England Journal of Medicine*, 333(9), 541-549.
- Diabetes, U. (2015). Diabetes in the UK 2012: Key statistics on diabetes. 2012. *Diabetes UK, London*.
- Donnelly, L., Doney, A., Hattersley, A., Morris, A., & Pearson, E. (2006). The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes. *Diabetic medicine*, 23(2), 128-133.
- Dresner, Alan, Didier Laurent, Melissa Marcucci, Margaret E. Griffin, Sylvie Dufour, Gary W. Cline, Lori A. Slezak et al., (1999), Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. *Journal of Clinical Investigation* 103, no. 2: 253.
- Duong, Janna K., Shaun S. Kumar, Carl M. Kirkpatrick, Louise C. Greenup, Manit Arora, Toong C. Lee, Peter Timmins et al., (2013), Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. *Clinical pharmacokinetics* 52, no. 5: 373-384.
- Evans, J. L., Goldfine, I. D., Maddux, B. A., & Grodsky, G. M. (2002). Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. *Endocrine reviews*, 23(5), 599-622.
- Foretz, M., & Viollet, B. (2011). Regulation of hepatic metabolism by AMPK. *Journal of hepatology*, 54(4), 827-829.
- Franks, P. W., Looker, H. C., Kobes, S., Touger, L., Tataranni, P. A., Hanson, R. L., & Knowler, W. C. (2006). Gestational Glucose Tolerance and Risk of Type 2 Diabetes in Young Pima Indian Offspring. *Diabetes*, 55(2), 460-465.
- Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L., Chu, X., Hillgren, K. M. (2010). Membrane transporters in drug development. *Nature reviews Drug discovery*, 9(3), 215-236.

- Gibaldi, M., & Koup, J. (1981). Pharmacokinetic concepts—drug binding, apparent volume of distribution and clearance. *European journal of clinical pharmacology*, 20(4), 299-305.
- Gong, L., Goswami, S., Giacomini, K. M., Altman, R. B., & Klein, T. E. (2012). Metformin pathways: pharmacokinetics and pharmacodynamics. *Pharmacogenetics and genomics*, 22(11), 820.
- Goodarzi, M. O., & Bryer-Ash, M. (2005). Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. *Diabetes, Obesity and Metabolism*, 7(6), 654-665.
- Graham, Garry G., Jeroen Punt, Manit Arora, Richard O. Day, Matthew P. Doogue, Janna Duong, Timothy J. Furlong et al., (2011), Clinical pharmacokinetics of metformin. *Clinical pharmacokinetics* 50, no. 2: 81-98.
- Griffin, Margaret E., Melissa J. Marcucci, Gary W. Cline, Kim Bell, Nicole Barucci, Dennis Lee, Laurie J. Goodyear, Edward W. Kraegen, Morris F. White, and Gerald I. Shulman.(1999), Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. *Diabetes* 48, no. 6: 1270-1274.
- Hardie, D. G. (2007). AMP-activated protein kinase as a drug target. *Annu. Rev. Pharmacol. Toxicol.*, 47, 185-210.
- Hardie, D. G. (2013). AMPK: a target for drugs and natural products with effects on both diabetes and cancer. *Diabetes*, 62(7), 2164-2172.
- Hediger, M. A., Clémenton, B., Burrier, R. E., & Bruford, E. A. (2013). The ABCs of membrane transporters in health and disease (SLC series): introduction. *Molecular aspects of medicine*, 34(2), 95-107.
- Hediger, M. A., Romero, M. F., Peng, J.-B., Rolfs, A., Takanaga, H., & Bruford, E. A. (2004). The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins. *Pflügers Archiv*, 447(5), 465-468.
- Hermann, L. (1979). Metformin: a review of its pharmacological properties and therapeutic use. *Diabete & metabolisme*, 5(3), 233-245.
- Hermann, L., Schersten, B., & Melander, A. (1994). Antihyperglycaemic Efficacy, Response Prediction and Dose—Response Relations of Treatment with Metformin and Sulphonylurea, Alone and in Primary Combination. *Diabetic medicine*, 11(10), 953-960.
- Hotamisligil, G. (2008). Inflammation and endoplasmic reticulum stress in obesity and diabetes. *International journal of obesity*, 32, S52-S54.
- Hotamisligil, G. S. (2006). Inflammation and metabolic disorders. *Nature*, 444(7121), 860-867.
- Ieiri, I., Higuchi, S., & Sugiyama, Y. (2009). Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics

of statins and other clinically relevant drugs. *Expert opinion on drug metabolism & toxicology*, 5(7), 703-729.

- Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Matthews, D. R. (2012). Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes care*, 35(6), 1364-1379.
- Itoda, M., Saito, Y., Maekawa, K., Hichiya, H., Komamura, K., Kamakura, S., Ozawa, S. (2004). Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1). *Drug metabolism and pharmacokinetics*, 19(4), 308-312.
- Jacobs, C., Pearce, B., Du Plessis, M., Hoosain, N., & Benjeddou, M. (2014). Genetic polymorphisms and haplotypes of the organic cation transporter 1 gene (SLC22A1) in the Xhosa population of South Africa. *Genetics and molecular biology*, 37(2), 350-359.
- Jonker, J. W., & Schinkel, A. H. (2004). Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). *Journal of Pharmacology and Experimental Therapeutics*, 308(1), 2-9.
- Kahn, S. (2003). The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. *Diabetologia*, 46(1), 3-19.
- Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014). Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. *The Lancet*, 383(9922), 1068-1083.
- Kelley, D. E., He, J., Menshikova, E. V., & Ritov, V. B. (2002). Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. *Diabetes*, 51(10), 2944-2950.
- Kerb, Reinhold, Ulrich Brinkmann, Natalia Chatskaia, Dmitry Gorbunov, Valentin Gorboulev, Esther Mornhinweg, Andrea Keil, Michel Eichelbaum, and Hermann Koepsell. (2002), Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. *Pharmacogenetics and Genomics* 12, no. 8: 591-595.
- Kimura, N., Okuda, M., & Inui, K.-i. (2005). Metformin transport by renal basolateral organic cation transporter hOCT2. *Pharmaceutical research*, 22(2), 255-259.
- Kong, Augustine, Valgerdur Steinthorsdottir, Gisli Masson, Gudmar Thorleifsson, Patrick Sulem, Soren Besenbacher, Aslaug Jonasdottir et al., (2009) Parental origin of sequence variants associated with complex diseases. *Nature* 462, no. 7275: 868.
- Krausova, L., Stejskalova, L., Wang, H., Vrzal, R., Dvorak, Z., Mani, S., & Pavek, P. (2011). Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene. *Biochemical pharmacology*, 82(11), 1771-1780.

- Kulkarni, R. N., Brüning, J. C., Winnay, J. N., Postic, C., Magnuson, M. A., & Kahn, C. R. (1999). Tissue-specific knockout of the insulin receptor in pancreatic β cells creates an insulin secretory defect similar to that in type 2 diabetes. *Cell*, 96(3), 329-339.
- Landau, B. R., Wahren, J., Chandramouli, V., Schumann, W. C., Ekberg, K., & Kalhan, S. C. (1996). Contributions of gluconeogenesis to glucose production in the fasted state. *Journal of Clinical Investigation*, 98(2), 378.
- Levitan, E. B., Song, Y., Ford, E. S., & Liu, S. (2004). Is nondiabetic hyperglycemia a risk factor for cardiovascular disease?: a meta-analysis of prospective studies. *Archives of internal medicine*, 164(19), 2147-2155.
- Magnusson, I., Rothman, D., Katz, L., Shulman, R., & Shulman, G. (1992). Increased rate of gluconeogenesis in type II diabetes mellitus. A ^{13}C nuclear magnetic resonance study. *Journal of Clinical Investigation*, 90(4), 1323.
- Mainous, A. G., Tanner, R. J., Scuderi, C. B., Porter, M., & Carek, P. J. (2016). Prediabetes Screening and Treatment in Diabetes Prevention: The Impact of Physician Attitudes. *The Journal of the American Board of Family Medicine*, 29(6), 663-671.
- Mate, M. (2015). The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c: corrigendum. *Pharmacogenetics and Genomics*, 25, 48-50.
- Meigs, J. B., Cupples, L. A., & Wilson, P. (2000). Parental transmission of type 2 diabetes: the Framingham Offspring Study. *Diabetes*, 49(12), 2201-2207.
- Metzger, B. E. (2007). Long-term outcomes in mothers diagnosed with gestational diabetes mellitus and their offspring. *Clinical obstetrics and gynecology*, 50(4), 972-979.
- Minematsu, T., & Giacomini, K. M. (2011). Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. *Molecular cancer therapeutics*, 10(3), 531-539.
- Moghissi, Etie S., Mary T. Korytkowski, Monica DiNardo, Daniel Einhorn, Richard Hellman, Irl B. Hirsch, Silvio E. Inzucchi, Faramarz Ismail-Beigi, M. Sue Kirkman, and Guillermo E. Umpierrez. (2009) American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. *Diabetes care* 32, no. 6: 1119-1131.
- Nagai, Yoshio, Shin Yonemitsu, Derek M. Erion, Takanori Iwasaki, Romana Stark, Dirk Weismann, Jianying Dong et al., (2009). The role of peroxisome proliferator-activated receptor γ coactivator-1 β in the pathogenesis of fructose-induced insulin resistance. *Cell metabolism* 9, no. 3: 252-264.
- Nakagami, T., Qiao, Q., Tuomilehto, J., Balkau, B., Tajima, N., Hu, G., & Borch-Johnsen, K. (2006). Screen-detected diabetes, hypertension and hypercholesterolemia as predictors of cardiovascular mortality in five

populations of Asian origin: the DECODA study. *European Journal of Cardiovascular Prevention & Rehabilitation*, 13(4), 555-561.

- Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009). Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes care*, 32(1), 193-203.
- Neschen, Susanne, Katsutaro Morino, Linda E. Hammond, Dongyan Zhang, Zhen-Xiang Liu, Anthony J. Romanelli, Gary W. Cline et al., (2005) Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA: glycerol-sn-3-phosphate acyltransferase 1 knockout mice. *Cell metabolism* 2, no. 1: 55-65.
- Nies, A. T., Hofmann, U., Resch, C., Schaeffeler, E., Rius, M., & Schwab, M. (2011). Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). *PLoS One*, 6(7), e22163.
- Nies, Anne T., Hermann Koepsell, Stefan Winter, Oliver Burk, Kathrin Klein, Reinhold Kerb, Ulrich M. Zanger, Dietrich Keppler, Matthias Schwab, and Elke Schaeffeler.(2009). Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. *Hepatology* 50, no. 4: 1227-1240.
- O'Rahilly, S., Rudenski, A., Burnett, M., Nugent, Z., Hosker, J., Darling, P., & Turner, R. (1986). Beta-cell dysfunction, rather than insulin insensitivity, is the primary defect in familial type 2 diabetes. *The Lancet*, 328(8503), 360-364.
- Otsuka, M., Matsumoto, T., Morimoto, R., Arioka, S., Omote, H., & Moriyama, Y. (2005). A human transporter protein that mediates the final excretion step for toxic organic cations. *Proceedings of the National Academy of Sciences of the United States of America*, 102(50), 17923-17928.
- Porta, V., Schramm, S. G., Kano, E. K., Koono, E. E., Armando, Y. P., Fukuda, K., & dos Reis Serra, C. H. (2008). HPLC-UV determination of metformin in human plasma for application in pharmacokinetics and bioequivalence studies. *Journal of pharmaceutical and biomedical analysis*, 46(1), 143-147.
- Raghavan, S., Porneala, B., McKeown, N., Fox, C. S., Dupuis, J., & Meigs, J. B. (2015). Metabolic factors and genetic risk mediate familial type 2 diabetes risk in the Framingham Heart Study. *Diabetologia*, 58(5), 988-996.
- Ramachandran, A., Snehalatha, C., Mary, S., Mukesh, B., Bhaskar, A., & Vijay, V. (2006). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). *Diabetologia*, 49(2), 289-297.
- Randle, P., Garland, P., Hales, C., & Newsholme, E. (1963). The glucose fatty-acid cycle its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. *The Lancet*, 281(7285), 785-789.

- Randle, P., Garland, P., Newsholme, E., & Hales, C. (1965). The glucose fatty acid cycle in obesity and maturity onset diabetes mellitus. *Annals of the New York Academy of Sciences*, 131(1), 324-333.
- Randle, P., Newsholme, E., & Garland, P. (1964). Regulation of glucose uptake by muscle. 8. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan-diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. *Biochemical Journal*, 93(3), 652.
- Ritov, V. B., Menshikova, E. V., He, J., Ferrell, R. E., Goodpaster, B. H., & Kelley, D. E. (2005). Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. *Diabetes*, 54(1), 8-14.
- Ritzel, R. A., Butler, A. E., Rizza, R. A., Veldhuis, J. D., & Butler, P. C. (2006). Relationship between β -cell mass and fasting blood glucose concentration in humans. *Diabetes care*, 29(3), 717-718.
- Roden, M., Price, T. B., Perseghin, G., Petersen, K. F., Rothman, D. L., Cline, G. W., & Shulman, G. I. (1996). Mechanism of free fatty acid-induced insulin resistance in humans. *Journal of Clinical Investigation*, 97(12), 2859.
- Roden, Michael, Harald Stingl, Visvanathan Chandramouli, William C. Schumann, Astrid Hofer, Bernard R. Landau, Peter Nowotny, Werner Waldhäusl, and Gerald I. Shulman.(2000). Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans. *Diabetes* 49, no. 5: 701-707.
- Rowland, M., & Tozer, T. N. (1995). *Clinical pharmacokinetics: concepts and applications* (Vol. 3): Williams & Wilkins Baltimore.
- Rowland, M., & Tozer, T. N. (2005). *Clinical pharmacokinetics pharmacodynamics*: Lippincott Williams and Wilkins Philadelphia.
- Sam, W. J., Roza, O., Hon, Y. Y., Alfaro, R. M., Calis, K. A., Reynolds, J. C., & Yanovski, J. A. (2017). Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance. *The Journal of Clinical Pharmacology*, 57(2), 219-229.
- Samuel, Varman T., Zhen-Xiang Liu, Xianqin Qu, Benjamin D. Elder, Stefan Bilz, Douglas Befroy, Anthony J. Romanelli, and Gerald I. Shulman. (2004). Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. *Journal of Biological Chemistry* 279, no. 31: 32345-32353.
- Samuel, Varman T., Zhen-Xiang Liu, Amy Wang, Sara A. Beddow, John G. Geisler, Mario Kahn, Xian-man Zhang, Brett P. Monia, Sanjay Bhanot, and Gerald I. Shulman. (2007). Inhibition of protein kinase C ϵ prevents hepatic insulin resistance in nonalcoholic fatty liver disease. *Journal of Clinical Investigation* 117, no. 3: 739.
- Savage, David B., Cheol Soo Choi, Varman T. Samuel, Zhen-Xiang Liu, Dongyan Zhang, Amy Wang, Xian-Man Zhang et al., (2006). Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide

- inhibitors of acetyl-CoA carboxylases 1 and 2. *Journal of Clinical Investigation* 116, no. 3: 817.
- Savage, D. B., Petersen, K. F., & Shulman, G. I. (2007). Disordered lipid metabolism and the pathogenesis of insulin resistance. *Physiological reviews*, 87(2), 507-520.
- Shargel, L., & Andrew, B. (1993). *Applied biopharmaceutics and pharmaceuticals*: Prentice-Hall International Co., Appleton & Lange, London.
- Shoelson, S. E., Lee, J., & Goldfine, A. B. (2006). Inflammation and insulin resistance. *The Journal of clinical investigation*, 116(7), 1793-1801.
- Shu, Yan, Maya K. Leabman, Bo Feng, Lara M. Mangravite, Conrad C. Huang, Doug Stryke, Michiko Kawamoto et al., (2003). Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. *Proceedings of the National Academy of Sciences* 100, no. 10: 5902-5907.
- Shu, Y., Sheardown, S. A., Brown, C., Owen, R. P., Zhang, S., Castro, R. A., Burchard, E. G. (2007). Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. *The Journal of clinical investigation*, 117(5), 1422-1431.
- Shulman, G. I., Rothman, D. L., Jue, T., Stein, P., DeFronzo, R. A., & Shulman, R. G. (1990). Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by ¹³C nuclear magnetic resonance spectroscopy. *New England Journal of Medicine*, 322(4), 223-228.
- Singh, S., Usman, K., & Banerjee, M. (2016). Pharmacogenetic studies update in type 2 diabetes mellitus. *World Journal of Diabetes*, 7(15), 302.
- Somogyi, A., Stockley, C., Keal, J., Rolan, P., & Bochner, F. (1987). Reduction of metformin renal tubular secretion by cimetidine in man. *British journal of clinical pharmacology*, 23(5), 545-551.
- Stumvoll, M., Goldstein, B. J., & van Haefen, T. W. (2005). Type 2 diabetes: principles of pathogenesis and therapy. *The Lancet*, 365(9467), 1333-1346.
- SUR, D. (2014). A Tale Of Genetic Variation In The Human Slc22a1 Gene Encoding Oct1 Among Type 2 Diabetes Mellitus Population Groups Of West Bengal, INDIA.
- Takane, H., Shikata, E., Otsubo, K., Higuchi, S., & Ieiri, I. (2008). Polymorphism in human organic cation transporters and metformin action.
- Thomas, C. C., & Philipson, L. H. (2015). Update on diabetes classification. *Medical Clinics of North America*, 99(1), 1-16.
- Triplitt, C., Solis-Herrera, C., Reasner, C., DeFronzo, R. A., & Cersosimo, E. (2015). Classification of diabetes mellitus.
- Trisnawati, S. K., & Setyorogo, S. (2013). Faktor risiko Kejadian diabetes melitus tipe II di puskesmas kecamatan cengkareng Jakarta Barat Tahun 2012. *Jurnal Ilmiah Kesehatan*, 5(1), 6-11.

- Tuomilehto, Jaakko, Jaana Lindström, Johan G. Eriksson, Timo T. Valle, Helena Hämäläinen, Pirjo Ilanne-Parikka, Sirkka Keinänen-Kiukaanniemi et al., (2001). Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *New England Journal of Medicine* 344, no. 18: 1343-1350.
- Umamaheswaran, G., Praveen, R. G., Damodaran, S. E., Das, A. K., & Adithan, C. (2015). Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients. *Clinical and experimental medicine*, 15(4), 511-517.
- Viollet, B., & Foretz, M. (2013). Revisiting the mechanisms of metformin action in the liver. Paper presented at the Annales d'endocrinologie.
- Weir, G. C., & Bonner-Weir, S. (2004). Five stages of evolving beta-cell dysfunction during progression to diabetes. *Diabetes*, 53(suppl 3), S16-S21.
- Xiao, Di, Yu Guo, Xi Li, Ji-Ye Yin, Wei Zheng, Xin-Wen Qiu, Ling Xiao et al., (2016). The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients. *International journal of endocrinology* 2016.
- Yu, Chunli, Yan Chen, Gary W. Cline, Dongyan Zhang, Haihong Zong, Yanlin Wang, Raynald Bergeron et al., (2002), Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. *Journal of Biological Chemistry* 277, no. 52: 50230-50236.
- Zarghi, A., Foroutan, S., Shafaati, A., & Khoddam, A. (2003). Rapid determination of metformin in human plasma using ion-pair HPLC. *Journal of pharmaceutical and biomedical analysis*, 31(1), 197-200.
- Zhang, Dongyan, Zhen-Xiang Liu, Cheol Soo Choi, Liqun Tian, Richard Kibbey, Jianying Dong, Gary W. Cline, Philip A. Wood, and Gerald I. Shulman. (2007). Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance. *Proceedings of the National Academy of Sciences* 104, no. 43: 17075-17080.
- Zhou, Gaochao, Robert Myers, Ying Li, Yuli Chen, Xiaolan Shen, Judy Fenyk-Melody, Margaret Wu et al., (2001). Role of AMP-activated protein kinase in mechanism of metformin action. *Journal of clinical investigation* 108, no. 8: 1167.